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Aims: For people with schizophrenia, non-adherence to antipsychotic medications may result 
in high use of health and other services. The objective of our research was to examine the 
economic consequences of non-adherence in patients with schizophrenia taking antipsychotic 
medication. 
 
Methods: Data were taken from QUATRO, a randomized controlled trial that drew a sample 
of adults with schizophrenia receiving psychiatric services in four European cities: 
Amsterdam, Leipzig, London and Verona. Trial inclusion criteria were a clinical diagnosis of 
schizophrenia, requiring on-going antipsychotic medication for at least one year following 
baseline assessment, and exhibiting evidence of clinical instability in the year prior to 
baseline. The patient-completed Medication Adherence Questionaire (MAQ) was used to 
calculate the 5-point Morisky index of adherence. Generalised linear models were developed 
to determine the effect of adherence on (i) health and social care and (ii) societal costs before 
and after treatment, taking into account other potential cost-influencing factors.  
 
Results: The effect of non-adherence on costs was mixed. For different groups of services, 
and according to treatment group assignment, non-adherence was both negatively and 
positively associated with costs.  
 
Conclusions: The impact of non-adherence on costs varies across the types of services used 
by individuals with schizophrenia.  
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Introduction 
 
Most people with schizophrenia use antipsychotic medication, which may be required to be 
taken indefinitely. A relatively high prevalence of non-adherence is observed among those 
prescribed antipsychotics. A review by Lacro (2002) found rates of non-adherence to 
antipsychotic medication ranged from 4% to 72% with a mean of 41%. Many patients 
experience unwanted side-effects, which are associated with non-adherence and low quality 
of life. Systematic reviews have consistently observed several other factors to be associated 
with non-adherence, such as drug and alcohol misuse, a lack of insight, a poor therapeutic 
alliance and the severity of symptoms (Kampman & Lehtinen, 1999; Lacro et al., 2002; Nose 
et al., 2003). 
 
People with schizophrenia often need and use a range of health and other services, 
particularly in periods of psychosis and low functioning, which may be related to non-
adherence to antipsychotic medications and may result in high costs. For example, Weiden et 
al. (2004b) found a significant association between measures of partial adherence and the 
probability of rehospitalisation in a sample of patients with schizophrenia. We used data 
collected in a European study of people with schizophrenia to examine the economic 
consequences of non-adherence in patients with schizophrenia taking antipsychotic 
medication. The aim of this study was to determine the impact of non-adherence to 
medication on service use costs attributable to schizophrenia. 
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Methods 
 
QUATRO study 
 
We conducted secondary analyses of data from QUATRO, a randomized controlled trial that 
sampled adults with schizophrenia receiving psychiatric services in four cities: Amsterdam 
(The Netherlands), Leipzig (Germany), London (United Kingdom) and Verona (Italy). Each 
sample was recruited from patient records at local in-patient and community settings in 
2002/3 (Gray et al., 2006). 
 
Patients included in QUATRO had a clinical diagnosis of schizophrenia (confirmed by the 
Item Group Checklist of the Schedule for Clinical Assessment in Neuropsychiatry), exhibited 
evidence of clinical instability in the year prior to baseline (that is, one or more of the 
following occurred in the previous 12 months: one or more hospital admissions on mental 
health grounds, a change in type of dose of antipsychotic medication, planned or actual 
increased frequency of contact with mental health services, and indications of clinical 
instability reported by relatives, carers or the clinical team), and required on-going 
antipsychotic medication for at least one year following baseline assessment (Gray et al., 
2006). Written, informed consent was obtained from all participants. All sites gained full 
approval for the study from local research ethics committees (institutional review board). 
 
QUATRO was a two-arm randomized trial of the effectiveness and cost-effectiveness of 
adherence therapy (referred to hereafter as ‘treatment’) compared to standard health 
education in improving health-related quality of life for people with schizophrenia (Gray et 
al., 2006; Patel et al., 2011). Interviews at baseline and after 12 months were conducted by 
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researchers blinded to trial allocation. Patients were not blinded, but were not told which 
intervention was regarded by investigators as experimental. 
 
Adherence to medication was based on patient responses on the Medication Adherence 
Questionaire (MAQ), summed to obtain the 5-point Morisky score, ranging from 0 (poor 
adherence) to 4 (good adherence) (Morisky et al., 1986). This scale is widely used to assess 
adherence (Shalansky, 2004; Day et al., 2005). For the purpose of our new analyses, values 
0-2 were interpreted as non-adherence, as per the classification used by the QUATRO team 
(Gray et al., 2006). Other clinical measures were the mental component summary score on 
the Medical Outcome Study (MOS) 36-Item Short Form Health Survey (SF-36) (Ware & 
Sherbourn, 1992) and the Brief Psychiatric Rating Scale – Expanded (BPRS-E) (Lukoff et 
al., 1986; Ventura et al., 1993). 
 
The Client Service Receipt Inventory (CSRI) (Beecham & Knapp, 1992) collected service 
use data for a three-month retrospective period in face-to-face interviews with study 
participants. That is, service use data for the three months prior to baseline and for the three 
months prior to the follow-up visit (12 months after baseline). Other data collected in the 
interview were demographic characteristics, accommodation, living situation, employment, 
and roles of informal carers. Local-language, validated versions were available from the 
EPSILON study (Chisholm et al., 2000).  
 
We are primarily interested in direct health and social care costs (medications, special (non-
hospital) accommodation, inpatient stays, outpatient visits, community-based day services 
and community-based professional contacts), and societal costs (health and social care plus 
criminal justice, informal care and cost of lost employment)(McCrone, 2011). Unit costs for 
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services were estimated at 2003 price levels (the most recent study year for which financial 
information was expected to be available at the time of the trial) in each study site (Patel, 
2006). National average wage levels were used to value lost employment and informal care 
cost. Because study centers were across four countries, unit costs were converted to a 
common basis using purchasing power parity (PPP)-adjusted Euros (Patel, 2006). Previous 
work demonstrated the importance of indirect costs in overall economic impact of 
schizophrenia (Knapp et al., 2004b). Service use frequency was multiplied by the unit cost of 
each service to estimate service use costs for each individual in the study.  
 
Statistical methods 
 
We examined the effect of adherence on costs before and after treatment, taking into account 
other potential cost-influencing factors. An indicator variable for adherence status was 
included, as was its interaction with treatment. We assumed no interaction between time and 
adherence. That is, we assumed that the relationship between non-adherence and costs would 
not differ between baseline and at the 12 month follow-up. 
 
The analyses tested models where costs were thought to be affected by demographic 
characteristics, whether or not the study participant was randomized to receive the treatment 
or standard health education, whether or not the individual was adherent to medication, the 
interaction of treatment assignment and adherence status and random error. A value of zero 
was assigned for treatment effect for all individuals at baseline as at this point no actual 
treatment was received. The model can be expressed algebraic as follows:  
i
k
j
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where nonadhi = 1 if the patient non-adherent or nonadhi = 0 if the patient is adherent.,  
 
As the outcome was modeled with logistic regression, the interaction term required careful 
interpretation (Menard, 2002). If the interaction between adherence and treatment was 
significant, the effect of non-adherence on costs was β3 (the coefficient of the non-adherence 
variable) for those who did not receive treatment and β3+β4 (the sum of the coefficients of the 
non-adherence variable and the treatment by non-adherence interaction) for those who did. 
Standard errors are clustered by individual to account for the non-independence between the 
two time points for each individual. 
 
Patient-specific characteristics, identified from previous literature as potentially relevant to 
understanding cost variations, were examined: age, sex,  severity of illness (BPRS-E, SF-36 
mental component score), whether or not living alone, education level (whether or not 
completed further or tertiary education), ethnicity (white European or other ethnic 
background), familiarity with medication (measured by years on medication), and study site 
(Weiden et al., 2004b; Becker et al., 2007). Because the  clinical measures were correlated, 
only the score with the greater significance level was retained in each analysis. This reduced 
the potential for bias due to omitted variables. 
 
The primary analysis examined the association between non-adherence and health and social 
care  and societal costs. Some previous studies looked at the association between non-
adherence and the cost of inpatient stays and community-based care (Svarstad et al., 2001; 
Knapp et al., 2004a; Weiden et al., 2004b). To allow for comparison with these studies, we 
conducted secondary analyses examining the association between non-adherence and the 
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costs associated with  inpatient stays and community-based day services. Included in 
community-based day services were community mental health centre visits, day care, group 
therapy and use of sheltered workshops and specialist education.  
 
Four patients were missing data on two covariates and 51 were missing data on one variable 
only. Length of time on medication was the variable with the most missing data. These data 
were not provided by 43 individuals. Other variables with missing data were the Morisky 
self-assessed adherence score which was missing for 13 individuals, level of education (not 
reported by two individuals) and whether or not they lived alone (missing for one individual). 
 
Excluding the variable on length of time on medication would reduce the number of 
observations in the dataset by 10%. This variable was assumed to be missing at random; i.e. a 
patient would be no more or less likely to report this information based on the length of time 
they were on medication. Similarly, there would be no reason to not report this information 
based on their service use. Making this assumption allowed us to impute missing values using 
multiple imputation. With respect to the other variables with missing data, we concluded that 
there are reasons why a patient would not want to disclose that they had a low level of 
educational qualifications, lived alone or had not taken their medication. For this reason, and 
the fact that very few observations would be lost by excluding observations where one of 
these three variables was missing, we did not impute missing values on these variables. 
 
Due to skewness in the cost distribution, generalised linear models (GLM) were estimated. 
The Park test was employed to determine the appropriate distribution and link functions 
(Mullahy, 1998). In the secondary analyses of inpatient and community-based day service use 
costs, two-part modeling (Mullahy, 1998) was needed because some patients did not use 
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particular subsets of services (zero costs). First we ran a logistic regression on whether or not 
costs were incurred, and then we ran a GLM on costs for the subsample who used services.  
 
Analysis was undertaken using STATA 10.1 (STATA, 2001). Robust standard errors were 
estimated to account for heteroscedasticity. Significance values below 0.05 were deemed 
statistically significant. Significance values between 0.1 and 0.05 were identified to indicate 
associations that approached statistical significance. 
 
Results 
 
Sample characteristics 
 
Four hundred and nine adults were recruited across the four sites (Table 1). Approximately 
30% of respondents had Morisky scale scores reflecting non-adherence to their medication. 
Of the 409 patients interviewed at baseline, 357 were also interviewed at 12 months. There 
were no significant differences in characteristics between individuals who did or did not 
complete a follow-up interview (Table 1).  
 
Health and social care costs 
 
Our first model estimated the significance of non-adherence and other factors on health and 
social care costs, based on 770 observations across the two time points. A single GLM model 
was estimated as all individuals with complete data across the independent variables had non-
zero health and social care costs. The effect of non-adherence was not statistically 
significantly associated with health and social care costs (Table 2; p=0.137). The treatment-
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adherence interaction variable approaches statistical significance (p=0.055), suggesting that 
the effect of non-adherence on costs may differ by treatment group. For non-adherent patients 
in the control group, health and social care costs were, on average, 20% lower than for 
patients who adhereded to their medication. Within the treatment group, these costs were, on 
average, 50% higher. These differences, while potentially important, were not statistically 
significant because of relatively large standard errors in the estimates. 
 
Of the remaining factors considered, higher costs were incurred for people who lived with 
others (compared to living alone), and men had higher health and social care costs than 
women. There was also a positive association between severity of symptoms and health and 
social care costs. 
 
 
Societal costs 
 
For societal costs a two-part model was again unnecessary as every patient had non-zero 
costs. Patients who reported non-adherence had significantly lower societal costs than those 
reporting adherence (Table 2; p=0.049). The interaction of treatment and adherence 
approached statistical significance (p=0.065). Non-adherence is associated with significantly 
lower costs among those who did not receive treatment but is not among those that did. 
Societal costs were, on average, over 20% lower among non-adherent patients who did not 
receive treatment. Individuals who lived with others had significantly higher societal costs 
compared to those who lived alone, and White Europeans had significantly higher costs 
compared to repondents of other ethnicities. There was also a positive association between 
symptom severity and societal costs. 
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Component costs  
 
Analyses of inpatient stay costs and community-based day service costs required two-part 
models because, for each, a significant number of individuals in the sample did not use these 
service.  
 
Inpatient stays 
 
Logistic regression (the first part of the two-part process) did not find a statistically 
significant association between non-adherence and inpatient stays (Table 3). Individuals who 
lived alone were less likely to have had an inpatient stay as compared to those who lived with 
others. Greater severity of symptoms (measured by BPRS-E) was associated with a greater 
probability of an inpatient stay. The model correctly predicted whether or not inpatient stays 
had occurred for 65% of cases. 
 
The second part of the analysis (GLM) found inpatient costs were not significantly associated 
with any of the factors considered (Table 3). The interaction of treatment and non-adherence 
approached statistical significance (p=0.081), however, suggesting again that the direction of 
the effect of non-adherence on costs differed according to treatment group assignment. 
Among patients who received treatment there was a trend towards inpatient costs being 
significantly higher for non-adherent patients compared to adherent patients (p=0.086). 
Indeed, on average inpatient costs were over twice as great in the non-adherent group. Ethnic 
minority respondents had significantly lower inpatient costs as compared to White European 
respondents (p=0.045).  
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Community-based day services 
 
In a logistic regression model of whether or not community-based day services were used, 
living alone was significant (Table 4). Individuals who lived alone were twice as likely to 
have used community-based day services compared to those who lived with others. There 
was also a trend (p=0.069) towards longer time on medication being associated with greater 
probability of having used community-based day services. This model correctly predicted 
61% of cases. 
 
The interaction between treatment and non-adherence approached statistical significance 
(p=0.075). Among those receiving treatment, the odds of using community-based day 
services were significantly lower for those who were non-adherent compared to those were 
adherent (odds ratio=0.35, p-value=0.021) . 
 
Among those who used community-based day services, the GLM model found a trend 
(p=0.059) towards non-adherence being associated with lower community-based day service 
costs compared to those who were adherent (Table 4). On average, costs for community-
based day services were 50% lower among non-adherent patients compared to those who 
adhered.  
Sensitivity analyses 
 
We examined the impact of choice of threshold in the Morisky score used to determine non-
adherence. Shalansky (2004) suggested using other thresholds to trade-off sensitivity and 
positive predictive value of the scale in detecting ‘true’ non-adherent patients. Analyses were 
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conducted to determine if using a threshold score of 3 on the Morisky score to define non-
adherence would impact on the results.  
 
Using the lower threshold level suggested that 52.8% of the sample were non-adherent at 
baseline (whereas at the higher threshold the figure was 30%). For all cost measures the 
effect of non-adherence was statistically non-significant.  
 
Discussion 
 
Main findings  
 
Our results suggest that non-adherence is not significantly associated with total health and 
social care costs. Costs from a societal perspective were in fact lower among those who did 
not adhere to their medication. 
 
 
Limitations 
 
One limitation of the study was the relatively small sample, so results may not be 
generalisable to wider populations. The effect of ethnicity may not be consistent across 
minority ethnic groups, but the limited sample size made it infeasible to test for differences 
between specific minority ethnic groups.  
 
The sample size calculation for the QUATRO trail was based on the SF-36 mental 
component summary score (Gray et al., 2006). Retrospective estimation of the power based 
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on service use (and, by extension, costs) was difficult as service use typically has high 
variability, leading to underestimation of power (Gray et al., 1997). Based on the standard 
error observed in the analysis of health and social care costs, the study sample size was 
sufficient to observe a 44% difference in costs with 80% power. With respect to societal 
costs, the study sample was sufficient to observe a 38% difference in costs with 80% power. 
These estimates do not, however, account for there being four distinct study sites within 
which we would expect a degree of similarity in service provision. 
 
Relying on a multi-centre, cross-country sample has advantages, but service systems differ 
between sites, and unit costs are not always available (Patel, 2006). However, Heider et al. 
(2009), following samples of people with schizophrenia in France, Germany and the UK for 
two years, found differences in costs for individual services, but that total adjusted costs of 
health services varied rather less. The QUATRO study did not collect information on some 
potentially relevant dimensions, including general health status, whether co-morbidity was 
present, use of illegal drugs or alcohol abuse. 
 
Because the Morisky scale relies on self-report, it runs the risk of underestimating non-
adherence. The prevalence of non-adherence in studies where self-reporting is used will tend 
to be underestimated as some patients are unaware of mistakes they are making in the 
medication regime or will choose to not report non-adherence (Byerly et al., 2005; Velligan 
et al., 2006). The observed rate of non-adherence was relatively low when compared across 
studies of patients taking antipsychotic medication (Lacro et al., 2002).  The advantage of 
using self-reported information is that it is more efficient and less costly than other methods 
(Thompson et al., 2000).  
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A further limitation is that the QUATRO study  duration was short relative to a lifetime of 
schizophrenia and the (probable) long-term impacts of non-adherence. Some of the negative 
impacts of non-adherence and effects on service use might not have been observed within the 
study period. 
 
Despite these limitations, our analyses offer useful new information on the relationship 
between non-adherence and costs. Unlike previous studies that have predominantly examined 
this association using cross-sectional data, the 12-month  design allowed for examination of 
change over time in the associations assessed. The study also included a valid and reliable 
scale for assessing adherence and detailed service use data. 
 
 
Findings from other studies 
 
Our findings are similar to those of Gilmer et al. (2004) who found that the impact of non-
adherence on health care costs varied by the source of costs.In their study hospital costs were 
significantly higher for the non-adherent group but total health care expenditure was 
significantly lower. Similar results regarding the association between non-adherence and 
inpatient costs were obeserved in other studies. Svarstad et al. (2001) found non-adherers 
(patients with a three-month gap in medication claims) were more likely to have been 
rehopsitalised and incurred significantly higher inpatient costs. Weiden et al. (2004a) 
observed that gaps in medication therapy, based on prescription claims, were positively 
correlated with risk of hospitalisation. Knapp et al. (2004a) observed a trend towards a 
significant association between inpatient visits and non-adherence.  
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In order to shed light on the finding that non-adherence was associated with significantly 
lower societal costs we looked at each of the cost categories to determine for which services 
this relationship was strongest. The data show that outpatient and community services went 
down over time for the sample as a whole, but the decrease in use of these services was 
greater among non-adherent patients. This was also true of informal care.  
 
 
 
 As in Knapp et al. (2004a), non-adherence was also associated with lower community-based 
day service costs among individuals in the intervention group (when these services were 
used). These patterns of association may occur if non-adherent patients put off seeking help 
when their symptoms return. Or by using fewer community services and receiving less 
informal care, the risk increases that they become non-adherent. This will also depend on the 
way services are organized and the ease with which they can access services. Additionally, 
the relevance to the findings of the nature of the sample must be considered. The criteria for 
inclusion in the study that individuals’ treatment in the year before baseline must have been 
clinically unstable may suggest an underlying difficulty in engaging with non-acute services 
as opposed to a difficulty with medication taking only. Interventions which develop 
relationships between patients and therapeutic staff have been found to be effective in 
improving compliance (Kuipers, 1996). 
 
The results from the QUATRO trial did not find an association between adherence therapy 
and adherence to medication at follow-up (Gray et al., 2006). The findings from the present 
study suggest that while the intervention did not impact non-adherence, it did impact on the 
association between non-adherence and costs. That is, among those receiving adherence 
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therapy there was a trend towards lower inpatient costs and higher odds of using community-
based services among those who report adherence to medication as compared to those who 
did not. This finding is difficult to interpret, but may in part be suggesting that for some 
individuals, the intervention encouraged engagement with services. 
 
We observed lower health and social care and societal costs among patients living alone, 
suggesting that when individuals with schizophrenia live with family and/or friends, the latter 
may play a role in encouraging patients to access services. However, living alone was also 
significantly associated with a higher probability of using community-based day services, so 
informal care may act as a substitute for community-based day services but as a complement 
to other health and social care services. Alternatively, patients living alone may have been 
better functioning and therefore had the skills to live alone. The modeling corrected for 
severity of illness but may not have accounted for all aspects of functioning. 
 
Our results suggest that the impact of non-adherence varies by type of services used by 
people with schizophrenia: adherence interventions have the potential to reduce some costs. 
Attempts to improve engagement with community-based services AND adherence to 
medication, while potentially increasing costs, may benefit individuals with schizophrenia. 
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Table 1: Characteristics of QUATRO study sample at baseline: overall, completers and non-
completers 
 
Characteristic 
 
Completers 
(n=357) 
Non-completers 
(n=52) 
Overall 
(n=409) 
Centre: N (%) 
  Amsterdam 
  Leipzig 
  London 
  Verona 
 
87 (24.4) 
81 (22.7) 
80 (22.4) 
109 (30.5) 
 
13 (25.0) 
16 (30.8) 
12 (23.1) 
11 (21.2) 
 
100 (24.5) 
97 (23.7) 
92 (22.5) 
120 (29.3) 
Age: mean (sd) 41.7 (11.5) 40.3 (11.4) 41.5 (11.5) 
Sex: % male 59.9% 59.6% 59.9% 
Ethnicity: % White European 75.1% 80.8% 75.8% 
Education: % with 
further/tertiary qualifications 
 
32.4% 
 
32.7% 
 
32.4% 
Years using antipsychotics: 
mean (sd) 
 
13.9 (9.9) 
 
11.6 (9.8) 
 
13.7 (9.9) 
Living situation: % living 
alone 
40.2% 42.3% 40.4% 
Morisky scale total score: 
mean(sd) 
3.0 (1.2) 2.9 (1.2) 2.9 (1.2) 
Per cent non-adherent to 
medication at baseline * 
 
30.5% 
 
28.2% 
 
30.3% 
SF-36 mental component 
score: mean (sd) 
39.1 (11.9) 40.1 (10.7) 39.2 (11.7) 
BPRS-E total score: mean (sd) 45.0 (13.0) 46.1 (13.5) 45.2 (13.0) 
 
* Based on Morisky total scores of 0, 1 or 2 indicating non-adherence 
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Table 2: Generalised linear model of factors associated with health and social care and 
societal costs (n=770 observations) 
 
 Health and social care 
costs 
Societal costs 
Potentially associated factors Coefficient 
(p-value) 
Coefficient 
(p-value) 
Treatment… 
…relative to no treatment 
-0.15 (0.316) -0.10 (0.493) 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
-0.30 (0.004) -0.33 (0.001) 
Non-adherent… 
…relative to adherent 
-0.20 (0.137) -0.23 (0.049) 
Intervention x Non-adherence 
interaction 
 
0.65 (0.055) 
 
0.53 (0.065) 
Age – 5 year increment 0.030 (0.351) -0.017 (0.523) 
Females… 
…relative to males 
-0.26 (0.036) -0.029 (0.788) 
 Severity of illness (BPRS-E score) 0.021 (0.001) 0.021 (0.001) 
Lives alone… 
…relative to lives with others 
-0.36 (0.005) -0.33 (0.004) 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.94 (0.001) 
0.38 (0.073) 
-0.26 (0.164) 
0.67 (0.001) 
0.088 (0.613) 
-0.32 (0.038) 
Education – further or tertiary... 
...relative to primary, secondary or 
general 
0.057 (0.641) 0.13 (0.214) 
Not White European… 
…relative to White-European 
-0.22 (0.137) -0.38 (0.004) 
Number of years on medication -0.0018 (0.789) 0.00036 (0.951) 
Constant 8.94 (0.001) 9.63 (0.001) 
Link function Log  
Distributional family Gamma 
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Table 3: Two-part model of factors associated with (i) use of inpatient services and (ii) 
inpatient costs among those who used inpatient services 
 
 
Potentially associated factors 
Logistic regression of 
inpatient services 
(n=765 observations) 
GLM of inpatient costs 
(n=288 observations) 
Odds ratio 
(p-value) 
Coefficient 
(p-value) 
Treatment… 
…relative to no treatment 
0.91 (0.714) -0.070 (0.742) 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
0.47 (0.001) -0.21 (0.239) 
Non-adherent… 
…relative to adherent 
1.34 (0.185) -0.096 (0.630) 
Intervention x Non-adherence 
interaction 
0.99 (0.992) 1.00 (0.081) 
Age (5 year increase in age) 1.00 (0.981) 0.0050 (0.902) 
Females… 
…relative to males 
0.97 (0.885) -0.17 (0.239) 
Severity of illness (BPRS-E score) 1.02 (0.007) 0.0077 (0.186) 
Lives alone… 
…relative to lives with others 
0.69 (0.032) -0.13 (0.418) 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
1.95 (0.012) 
4.66 (0.001) 
0.84 (0.524) 
1.13 (0.001) 
-0.29 (0.269) 
-0.48 (0.136) 
Education – further or tertiary... 
...relative to primary, secondary or 
general 
1.03 (0.880) 0.16 (0.375) 
Not White European… 
…relative to White European 
1.03 (0.893) -0.40 (0.045) 
Number of years on medication 0.99 (0.208) 0.0011 (0.911) 
Constant  9.60 (0.001) 
Link function  Log 
Distributional family  Gamma 
Link test p-value 0.4186  
Pearson’s chi-squared test p-value 0.2774  
Hosmer-Lemeshow chi-squared 
test 
p-value 
 
0.2809 
 
Likelihood ratio chi-squared p-
value 
0.0001  
Per cent correctly classified 65.26  
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Table 4: Two-part model of factors associated with (i) use of community-based day services 
and (ii) community-based day service use costs among those who used community-based day 
services 
 
Potentially associated factors Logistic regression of 
community-based day 
services 
(n=765 observations) 
GLM of community-based 
day service use costs 
(n=281 observations) 
Odds ratio 
(p-value) 
Coefficient 
(p-value) 
Treatment… 
…relative to no treatment 
1.36 (0.202) -0.89 (0.010) 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
1.00 (0.984) -0.028 (0.924) 
Non-adherent… 
…relative to adherent 
0.85 (0.433) -0.66 (0.059) 
Intervention x Non-adherence 
interaction 
0.41 (0.075) 1.05 (0.091) 
Age – in 5 year increments 1.04 (0.351) 0.13 (0.145) 
Females… 
…relative to males 
1.04 (0.806) -0.70 (0.013) 
Severity of illness (BPRS-E score) 1.01 (0.443) -0.0093 (0.483) 
Lives alone… 
…relative to lives with others 
2.09 (0.001) 0.19 (0.530) 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.82 (0.424) 
0.93 (0.781) 
1.35 (0.230) 
0.39 (0.327) 
0.55 (0.396) 
-0.36 (0.348) 
Education – further or tertiary... 
...relative to primary, secondary or 
general 
0.87 (0.429) 0.78 (0.013) 
Not White European… 
…relative to White European 
1.18 (0.487) -0.042 (0.900) 
Number of years on medication 1.02 (0.069) -0.019 (0.256) 
Constant  8.15 (0.001) 
Link function  Log 
Distributional family  Gamma 
Link test p-value 0.3144  
Pearson’s chi-squared test p-value 0.3273  
Hosmer-Lemeshow chi-squared 
test 
p-value 
 
0.5392 
 
Likelihood ratio chi-squared p-
value 
0.0001  
Per cent correctly classified 61.23  
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